Efficacy and Safety of Second‐Generation Antipsychotics for Irritability Associated With Autism Spectrum Disorder: A Systematic Review and Network Meta‐Analysis
Authors:
- Luis Phillipe Nagem LopesLLLuis Phillipe Nagem Lopes
- Mariana Del Grossi MouraMMMariana Del Grossi Moura
- Elisangela Costa LimaELElisangela Costa Lima
- Lauren Giustti MazzeiLMLauren Giustti Mazzei
- Cristiane de Cássia BergamaschiCBCristiane de Cássia Bergamaschi
- Flávia Casale AbeFAFlávia Casale Abe
- Jardel Corrêa de OliveiraJOJardel Corrêa de Oliveira
- Luciane Cruz LopesLLLuciane Cruz Lopes
Open Access
- 24 May 2026
- journal article
- review article
- Published by Wiley in Pharmacoepidemiology and Drug Safety
- Vol. 35 (6)
Abstract
Objective: To assess, by a systematic review and network meta‐analysis, the comparative efficacy and safety of second‐generation antipsychotics in managing aggressive behavior associated with autism spectrum disorder in children and adults. Methods: Searches were conducted in MEDLINE, Embase, CENTRAL, PsycINFO, LILACS, CINAHL, trial registries, and grey literature from database inception to July 2025. Randomized controlled trials comparing second‐generation antipsychotics with placebo or other antipsychotics in individuals with autism were included. Outcomes were irritability (Aberrant Behavior Checklist–Irritability subscale—ABC‐I), global clinical impression (CGI), treatment discontinuation, and central nervous system–related adverse events. Data extraction and risk‐of‐bias assessment (RoB 2.0) were performed independently. Certainty of evidence was evaluated using CINeMA. Frequentist random‐effects network meta‐analyses reported mean differences (MD) or relative risks (RR) with 95% confidence intervals (CI). Incoherence and small‐study effects were assessed. Results: Fourteen trials including 1195 children with autism were analyzed; no studies involved adults. Aripiprazole at low (MD: −5.83; 95% CI: −8.63, −3.02), recommended (MD: −5.69; 95% CI: −7.34, −4.04), and high doses (MD: −6.91; 95% CI: −10.04, −3.77), and recommended‐dose risperidone (MD: −6.91; 95% CI: −9.52, −4.31) reduced irritability versus placebo; lurasidone showed no benefit. No significant differences were observed for CGI. Recommended‐dose aripiprazole (RR: 0.57; 95% CI: 0.36, 0.90) and risperidone (RR: 0.29; 95% CI: 0.10, 0.83) lowered discontinuation risk. Both drugs increased sedation, drowsiness, and tremor. Evidence certainty ranged from very low to moderate. Head‐to‐head comparisons were inconclusive, and evidence was limited by the absence of adult studies and the small number of trials for some comparisons. Conclusions: Risperidone and aripiprazole reduce irritability in pediatric autism but increase sedation, drowsiness, and tremor. No robust differences between active treatments were identified. PROSPERO Registration: 42022353795Keywords
Funding Information
- Ministry of Health
- Conselho Nacional de Desenvolvimento Científico e Tecnológico (27423543/2021‐0)
This publication has 22 references indexed in Scilit:
- Atypical antipsychotics for autism spectrum disorder: a network meta-analysisCochrane Database of Systematic Reviews, 2025
- Pharmacological intervention for irritability, aggression, and self-injury in autism spectrum disorder (ASD)Cochrane Database of Systematic Reviews, 2023
- Systematic Review and Meta-analysis: Efficacy of Pharmacological Interventions for Irritability and Emotional Dysregulation in Autism Spectrum Disorder and Predictors of ResponseJournal of the American Academy of Child & Adolescent Psychiatry, 2022
- Using the Clinical Global Impression scale to assess social communication change in minimally verbal children with autism spectrum disorderAutism Research, 2021
- The pediatric psychopharmacology of autism spectrum disorder: A systematic review - Part I: The past and the presentProgress in Neuro-Psychopharmacology and Biological Psychiatry, 2021
- The Internal Structure of the Aberrant Behavior Checklist Irritability Subscale: Implications for Studies of Irritability in Treatment-Seeking Youth With Autism Spectrum DisordersBehavior Therapy, 2020
- Pharmacotherapy of Autism Spectrum Disorder: Results from the Randomized BAART Clinical TrialPharmacotherapy: The Journal of Human Pharmacology and Drug Therapy, 2019
- Antipsychotic Use Trends in Youth With Autism Spectrum Disorder and/or Intellectual Disability: A Meta-AnalysisJournal of the American Academy of Child & Adolescent Psychiatry, 2016
- Aggressive behavior problems in children with autism spectrum disorders: Prevalence and correlates in a large clinical sampleResearch in Autism Spectrum Disorders, 2014
- Metabolic and endocrine adverse effects of second-generation antipsychotics in children and adolescents: A systematic review of randomized, placebo controlled trials and guidelines for clinical practiceEuropean Psychiatry, 2011